Paul Larson

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

William J. Marks, Raymond T. Bartus, João Siffert et al. · The Lancet Neurology · 2010 · 680 citations

Life Sciences, Neurology, Neuroscience +12

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

William J. Marks, Jill L. Ostrem, L. Verhagen et al. · The Lancet Neurology · 2008 · 587 citations

Medicine, Neurology, Pharmacology +11

Safety and tolerability of putaminal <i>AADC</i> gene therapy for Parkinson disease

Chadwick W. Christine, Philip A. Starr, Paul Larson et al. · Neurology · 2009 · 431 citations · Full text

Medicine, Neurology, Pharmacology +17

Results from a phase I safety trial of <i>hAADC</i> gene therapy for Parkinson disease

Jamie L. Eberling, William J. Jagust, Chadwick W. Christine et al. · Neurology · 2008 · 367 citations

Medicine, Neurology, Neuroscience +17

Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson’s disease

Ro’ee Gilron, Simon Little, Randy Perrone et al. · Nature Biotechnology · 2021 · 356 citations · Full text

Life Sciences, Biomedical Engineering, Neuroscience +17